We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals

69 hedge funds and large institutions have $109M invested in Corbus Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 17

0% more funds holding

Funds holding: 69 → 69 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

1.36% less ownership

Funds ownership: 31.78% → 30.42% (-1.4%)

34% less call options, than puts

Call options by funds: $1.58M | Put options by funds: $2.37M

40% less capital inflows, than outflows

Capital inflows: $6.6M | Capital outflows: $11.1M

Holders
69
Holders Change
–
Holders Change %
0%
% of All Funds
1.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
27
Reduced
17
Closed
11
Calls
$1.58​M
Puts
$2.37​M
Net Calls
-⁠$795​K
Net Calls Change
-⁠$277​K

CRBP Hedge Fund Activity: Q3 2017 in Review

69 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2017, worth a combined $109M — up 8.6% from $101M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of CRBP and 10 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 27 added.

The largest buyer was Vanguard Group, adding an estimated $1.04M. The largest seller was Perceptive Advisors, cutting an estimated $5.33M.

  • 69 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $109M of Corbus Pharmaceuticals stock for Q3 2017, up 8.6% quarter-over-quarter.
  • 10 funds opened new Corbus Pharmaceuticals positions in Q3 2017 and 11 closed out, a net change of -1 holder.
  • The largest Corbus Pharmaceuticals buyer in Q3 2017 was Vanguard Group, an estimated $1.04M added.
  • The largest Corbus Pharmaceuticals seller in Q3 2017 was Perceptive Advisors, an estimated $5.33M sold.

Based on aggregated 13F filings for Q3 2017.